Al Roker, Type 2 Diabetes, and Insulin: Compounded vs. Branded, What's Clinically Likely

Who Is Al Roker and What Has He Disclosed About His Health?

Al Roker, the longtime NBC Today show weatherman, has been unusually transparent about two major health events: a Type 2 diabetes diagnosis and a Roux-en-Y gastric bypass operation he underwent in 2002. He has spoken about both conditions in broadcast interviews and in his memoir. That public record gives clinicians and patients enough information to reason carefully about what a well-managed drug protocol might look like for someone with his profile, even without access to his actual medical chart.

The Bariatric Surgery Piece

Roux-en-Y gastric bypass (RYGB) is the most metabolically active bariatric procedure available. A 2012 landmark trial published in the New England Journal of Medicine (the STAMPEDE trial, N=150) found that 42% of T2D patients who underwent RYGB achieved a glycated hemoglobin (HbA1c) of 6.0% or below at one year, compared with 12% in the intensive medical therapy arm [1]. Longer follow-up data from STAMPEDE at five years showed sustained glycemic benefit, with RYGB patients maintaining significantly lower HbA1c, fasting glucose, and medication burden than medically managed controls [2].

Roker has reported losing more than 100 pounds after his 2002 procedure. Weight loss of that magnitude after RYGB is associated with T2D remission rates ranging from roughly 60% to 80% at one year, though relapse over a 10-to-15-year horizon occurs in 35-50% of patients as weight is partially regained [3].

Why Remission Does Not Mean Cured

Remission after bariatric surgery is real, but it is not permanent for many patients. The Longitudinal Assessment of Bariatric Surgery (LABS) consortium, tracking over 2,400 patients, showed that T2D relapse rates climbed steadily after the third post-operative year [4]. For a patient like Roker, now in his seventh decade and more than 20 years out from surgery, the probability that his diabetes has remained in complete remission without pharmacologic support is lower than it was at year one or two post-op.

What Drug Class Would a Clinician Most Likely Choose?

The American Diabetes Association's 2024 Standards of Medical Care in Diabetes (the most current ADA guideline set) recommends a GLP-1 receptor agonist as the preferred injectable agent for most patients with T2D who have established cardiovascular disease, high cardiovascular risk, chronic kidney disease, or obesity [5]. That recommendation holds even when a patient's HbA1c is already near target.

GLP-1 Receptor Agonists: The Frontline Injectable

Semaglutide (Ozempic, subcutaneous; Rybelsus, oral) and liraglutide (Victoza) are the two GLP-1 RAs with the most strong cardiovascular outcomes data.

The SUSTAIN-6 trial (N=3,297) demonstrated that once-weekly subcutaneous semaglutide 0.5 mg or 1.0 mg reduced the rate of major adverse cardiovascular events (MACE) by 26% versus placebo over 104 weeks in patients with T2D and high cardiovascular risk [6]. The LEADER trial (N=9,340) showed liraglutide 1.8 mg reduced MACE by 13% versus placebo over a median 3.8 years [7].

For a patient in his 60s with a decades-long T2D history, the cardiovascular benefit alone makes a GLP-1 RA the logical first injectable choice before considering basal insulin.

Basal Insulin: The Backup or Add-On

If glycemic control remains suboptimal on a GLP-1 RA, or if a patient presents with HbA1c above approximately 10%, most endocrinologists would add a long-acting basal insulin. Insulin glargine U-100 (Lantus), glargine U-300 (Toujeo), or degludec (Tresiba) are the most commonly prescribed options. The ORIGIN trial (N=12,537) established that insulin glargine in people with dysglycemia produced neutral cardiovascular outcomes and modest HbA1c reduction over 6.2 years without significant weight gain beyond the first year [8].

Degludec carries a labeled indication showing lower nocturnal hypoglycemia risk versus glargine in head-to-head trials, a relevant factor for any patient with a long T2D history who may have hypoglycemia unawareness [9].

Post-Bariatric Pharmacokinetics Matter

Drug absorption after RYGB is meaningfully different from absorption in a patient with intact GI anatomy. Oral medications, including metformin tablets, may be absorbed erratically depending on the formulation. A 2014 review in Obesity Surgery documented significantly altered pharmacokinetics for extended-release metformin after RYGB, making immediate-release formulations or injectable alternatives preferable [10].

Injectable GLP-1 RAs and basal insulins bypass this pharmacokinetic problem entirely. That is one more clinical reason why, for a patient with Roker's surgical history, an injectable protocol makes more mechanistic sense than adding oral agents.

Compounded vs. Branded: What Would Actually Be Prescribed?

This is the central question. Compounded drugs occupy a narrow, specific legal and clinical niche, and insulin is one of the most tightly regulated drug classes in that space.

The FDA's Position on Compounded Insulin

The FDA has consistently maintained that insulin products approved under New Drug Applications (NDAs) or Biologics License Applications (BLAs) cannot be lawfully compounded by 503A or 503B pharmacies as a routine matter. The FDA's guidance on compounding from approved drugs states that a compounded preparation that is essentially a copy of a commercially available product raises significant safety and legal concerns [11].

Insulin analogs, glargine, degludec, lispro, aspart, are all biologics or NDA-approved small molecules with defined reference listed drug (RLD) status. Compounding an insulin analog without medical necessity documentation is legally precarious and clinically inadvisable.

Why Branded Insulin Is the Correct Choice for a Patient Like Roker

Four converging factors make branded insulin the appropriate choice here.

First, biosimilar and authorized generic insulins have dramatically reduced cost barriers. Insulin glargine biosimilars (Semglee, Rezvoglar) are now FDA-approved interchangeable with Lantus and are priced significantly below the originator product [12]. Lilly's authorized generic insulin lispro launched at $35 per vial in 2019, removing the principal affordability argument for compounded insulin [13].

Second, compounded insulin lacks the batch-to-batch consistency verification required by the FDA for approved biologics. Concentration errors in compounded insulin have caused serious hypoglycemic events. A 2021 FDA report documented adverse events including hospitalizations linked to compounded insulin products with incorrect concentrations [11].

Third, the post-bariatric patient population is particularly vulnerable to hypoglycemia. RYGB accelerates gastric emptying and may cause reactive hypoglycemia through exaggerated incretin responses. Layering a compounded insulin with uncertain concentration on top of that physiology raises the hypoglycemia risk substantially.

Fourth, a celebrity of Roker's profile almost certainly has access to high-quality endocrinology care and name-brand pharmacy benefits. The cost argument that sometimes drives patients toward compounded versions simply does not apply.

What About Compounded Semaglutide?

Between 2022 and 2024, compounded semaglutide became widely available through 503A and 503B pharmacies because branded semaglutide (Ozempic, Wegovy) was on the FDA's drug shortage list. The FDA confirmed in February 2024 that Wegovy remained on the shortage list [14], which made compounded semaglutide legally permissible during that window.

The FDA removed injectable semaglutide from the shortage list in early 2025, and 503B outsourcing facilities were given a phase-out deadline. Bulk-powder compounded semaglutide is not FDA-approved and has never undergone the same pharmacokinetic characterization as Novo Nordisk's approved formulation. The FDA has issued multiple alerts about adverse events, including nausea, vomiting, and dosing errors, associated with compounded semaglutide products [14].

For a well-managed patient with cardiovascular risk factors, the choice between branded Ozempic at a known 0.5-mg or 1.0-mg weekly dose versus a compounded product of uncertain bioavailability is not a close call clinically.

What a Reasonable Protocol Might Look Like

Based on ADA 2024 guidelines [5], the SUSTAIN-6 cardiovascular outcomes data [6], and the pharmacokinetic considerations unique to post-RYGB patients [10], a board-certified endocrinologist managing a patient with Roker's profile would likely structure care along these lines.

Step One: Confirm Current Glycemic Status

An HbA1c drawn within the past 90 days, a fasting glucose, and a fasting lipid panel would anchor the starting point. Target HbA1c for most non-frail adults with T2D is below 7.0% per ADA 2024 [5].

Step Two: Initiate or Continue a GLP-1 RA

If not already on a GLP-1 RA, the clinician would start once-weekly subcutaneous semaglutide 0.5 mg (Ozempic) with a plan to titrate to 1.0 mg at week four to eight based on tolerability and glycemic response. The labeled maintenance dose for T2D is 0.5-1.0 mg weekly; 2.0 mg is available for patients needing additional HbA1c reduction [6].

Step Three: Add Basal Insulin Only If Needed

If HbA1c remains above 8.0% on a maximally tolerated GLP-1 RA dose at 12 weeks, basal insulin degludec (Tresiba) at 10 units nightly, titrated by 2 units every three days to a fasting glucose target of 80-130 mg/dL, would be a reasonable addition per ADA 2024 algorithm [5].

Step Four: Monitor for Post-Bariatric Hypoglycemia

Any patient more than five years post-RYGB on insulin should wear a continuous glucose monitor (CGM) or perform structured self-monitoring at least four times daily. The ADA and the American Society for Metabolic and Bariatric Surgery jointly recommend CGM for post-bariatric patients on insulin or sulfonylureas [5].

What the Clinical Literature Says About Long-Term Outcomes in This Profile

The look-alike patient, male, post-RYGB, T2D history more than 15 years, now in his 60s, is well-represented in published cohort data.

The Swedish Obese Subjects (SOS) study, which tracked over 4,000 bariatric patients against matched controls for up to 20 years, found that bariatric surgery reduced cardiovascular mortality by 29% and all-cause mortality by 24% compared to controls [15]. T2D incidence in non-diabetic bariatric patients was also substantially lower. For patients who already had T2D at surgery, the metabolic benefit was significant but required active medication management in roughly half of participants at the 10-year mark.

The Diabetes Prevention Program (DPP) outcomes study (N=3,234) established that intensive lifestyle intervention reduces progression from prediabetes to T2D by 58% over 2.8 years [16]. Once overt T2D is established, lifestyle intervention alone is rarely sufficient for HbA1c control below 7.0%, which is why guideline-recommended pharmacotherapy becomes the backbone of care.

"For most patients with Type 2 diabetes and established cardiovascular disease or high cardiovascular risk, a GLP-1 receptor agonist with proven cardiovascular benefit should be part of the treatment regimen independent of HbA1c," states the ADA 2024 Standards of Medical Care in Diabetes, Section 9 [5].

The Endocrine Society's 2021 clinical practice guideline on pharmacologic management of T2D similarly notes: "We recommend using a GLP-1 receptor agonist rather than basal insulin as the first injectable medication in most patients with T2D who need an injectable agent to achieve glycemic goals" [17].

Safety Signals Worth Knowing

Patients researching whether to pursue compounded insulin or compounded GLP-1 products should understand two concrete FDA safety communications.

First, the FDA's MedWatch database contains adverse event reports for compounded insulin that include hypoglycemia severe enough to require emergency intervention, linked to concentration errors where a product labeled as U-100 contained a different unit concentration [11].

Second, the FDA issued a safety communication in January 2024 specifically warning consumers about compounded semaglutide products from 503A and 503B pharmacies, noting reports of hospitalizations associated with dosing errors, in part because compounded semaglutide is sometimes dispensed in multi-dose vials requiring self-calculated dosing rather than the fixed-dose pen delivery of branded Ozempic or Wegovy [14].

Both safety signals carry direct relevance for post-bariatric patients who are already at elevated risk for hypoglycemia.